Medical Cannabis in Pediatric Oncology: Friend or Foe?

Malach, Megan; Kovalchuk, Igor; Kovalchuk, Olga

doi:10.3390/ph15030359

Cited by 7 publications

(4 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because the ECS system develops early in life, and in utero exposure data show negative outcomes, extreme caution is recommended in the use of cannabis in children and adolescents. Nevertheless, numerous studies and cases show the safety and efficacy of cannabis in the treatment of pediatric epilepsy and chemotherapy-induced nausea and vomiting (reviewed in [ 385 ]). A recent survey-based study of the use of cannabis in pediatric oncology showed that out of 14 participants who reported the use of a cannabis oil formulation for either cancer treatment or symptom management, all experienced symptom improvement [ 384 ].…”

Section: Sex-specific Differences In Ecs Ethical Considerations Of Ca...mentioning

confidence: 99%

See 1 more Smart Citation

Use of Cannabis and Cannabinoids for Treatment of Cancer

Cherkasova

Wang

Gerasymchuk

et al. 2022

Cancers

View full text Add to dashboard Cite

The endocannabinoid system (ECS) is an ancient homeostasis mechanism operating from embryonic stages to adulthood. It controls the growth and development of many cells and cell lineages. Dysregulation of the components of the ECS may result in uncontrolled proliferation, adhesion, invasion, inhibition of apoptosis and increased vascularization, leading to the development of various malignancies. Cancer is the disease of uncontrolled cell division. In this review, we will discuss whether the changes to the ECS are a cause or a consequence of malignization and whether different tissues react differently to changes in the ECS. We will discuss the potential use of cannabinoids for treatment of cancer, focusing on primary outcome/care—tumor shrinkage and eradication, as well as secondary outcome/palliative care—improvement of life quality, including pain, appetite, sleep, and many more factors. Finally, we will complete this review with the chapter on sex- and gender-specific differences in ECS and response to cannabinoids, and equality of the access to treatments with cannabinoids.

show abstract

Section: Sex-specific Differences In Ecs Ethical Considerations Of Ca...mentioning

confidence: 99%

“…Accumulating preclinical evidence suggests that cannabis may in turn have antitumor effects and may be a promising agent in pediatric oncology. Still, its use in pediatric practice remains controversial and requires more research [ 385 ].…”

Section: Sex-specific Differences In Ecs Ethical Considerations Of Ca...mentioning

confidence: 99%

Use of Cannabis and Cannabinoids for Treatment of Cancer

Cherkasova

Wang

Gerasymchuk

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Most studies focus on the pharmacodynamics (PD) and the potential treatment effect of CBD and THC. In addition to the approved use for treatment-resistant epilepsy in pediatrics, research has explored the effect of CBD in oncology [ 145 ], autism spectrum disorder [ 146 ], severe behavioral problems in children with intellectual disability [ 147 ], fragile X syndrome [ 148 ], and complex motor disorder [ 149 ]. One clinical trial found that THC is a significant anti-nausea and anti-vomiting agent in the pediatric population.…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

show abstract

“…Cannabis-based therapies have emerged as a promising avenue for cancer treatment, primarily due to their potential to alleviate cancer symptoms and inhibit tumour growth (Malach et al, 2022;Morales & Jagerovic, 2021). However, alongside these promises, it is imperative to assess the safety considerations associated with these therapies rigorously.…”

Section: Safety Considerations and Clinical Trialsmentioning

confidence: 99%

Buds and Bugs: A Fascinating Tale of Gut Microbiota and Cannabis in the Fight Against Cancer

Al-Khazaleh,

Jaye,

Chang

et al. 2023

Preprint

View full text Add to dashboard Cite

Emerging research has revealed a complex bidirectional interaction between the gut microbiome and cannabis. Preclinical studies have demonstrated that the gut microbiota can significantly influence the pharmacological effects of cannabinoids. One notable finding is the ability of the gut microbiota to metabolise cannabinoids, including Δ^9-tetrahydrocannabinol (THC). This metabolic transformation can alter the potency and duration of cannabinoid effects, potentially impacting their efficacy in cancer treatment. Additionally, the capacity of gut microbiota to activate cannabinoid receptors through the production of secondary bile acids underscores its role in directly influencing the pharmacological activity of cannabinoids. While the literature reveals promising avenues for leveraging the gut microbiome-cannabis axis in cancer therapy, several critical considerations must be accounted for. Firstly, the variability in gut microbiota composition among individuals presents a challenge in developing universal treatment strategies. The diversity in gut microbiota may lead to variations in cannabinoid metabolism and treatment responses, emphasising the need for personalised medicine approaches. The growing interest in understanding how the gut microbiome and cannabis may impact cancer has created a demand for up-to-date, comprehensive reviews to inform researchers and healthcare practitioners. This review provides a timely and invaluable resource by synthesizing the most recent research findings and spotlighting emerging trends. A thorough examination of the literature on the interplay between the gut microbiome and cannabis, specifically focusing on their potential implications for cancer, is presented in this review to devise innovative and effective therapeutic strategies for managing cancer.

show abstract

Medical Cannabis in Pediatric Oncology: Friend or Foe?

Cited by 7 publications

References 99 publications

Use of Cannabis and Cannabinoids for Treatment of Cancer

Use of Cannabis and Cannabinoids for Treatment of Cancer

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Buds and Bugs: A Fascinating Tale of Gut Microbiota and Cannabis in the Fight Against Cancer

Contact Info

Product

Resources

About